Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients With Relapsed Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Oct 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Belantamab mafodotin (Primary) ; Carfilzomib (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
Indications Multiple myeloma
Focus Therapeutic Use

05 Oct 2023 Status changed from not yet recruiting to recruiting.
26 Apr 2023 The protocol has been amended as: 1) Number of treatment arms has been changed from 1 to 2. 2) Parallel Assignment has been implemented instead of Single Group Assignment.3) Planned number of patients has been changed from 55 to 83.
26 Apr 2023 Planned number of patients changed from 55 to 83.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com